Richard Baird
Overview
Explore the profile of Richard Baird including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1857
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Veach A, Stokes C, Knoepp J, Jumpponen A, Baird R
Microb Ecol
. 2017 Dec;
76(1):156-168.
PMID: 29204781
Nitrogen deposition alters forest ecosystems particularly in high elevation, montane habitats where nitrogen deposition is greatest and continues to increase. We collected soils across an elevational (788-1940 m) gradient, encompassing...
12.
Selby P, Lawler M, Baird R, Banks I, Johnston P, Nurse P
Ecancermedicalscience
. 2017 Mar;
11:ed63.
PMID: 28275394
Following the UK "Brexit" vote in June 2016, there are many uncertainties and risks for cancer research and cancer care in the UK. These are summarised and the importance of...
13.
Wan J, Massie C, Garcia-Corbacho J, Mouliere F, Brenton J, Caldas C, et al.
Nat Rev Cancer
. 2017 Feb;
17(4):223-238.
PMID: 28233803
Improvements in genomic and molecular methods are expanding the range of potential applications for circulating tumour DNA (ctDNA), both in a research setting and as a 'liquid biopsy' for cancer...
14.
Azaro A, Rodon J, Machiels J, Rottey S, Damian S, Baird R, et al.
Cancer Chemother Pharmacol
. 2016 Nov;
78(6):1185-1197.
PMID: 27796539
Purpose: Limited data are available on cabazitaxel pharmacokinetics in patients with renal impairment. This open-label, multicenter study assessed cabazitaxel in patients with advanced solid tumors and normal or impaired renal...
15.
Bruna A, Rueda O, Greenwood W, Batra A, Callari M, Batra R, et al.
Cell
. 2016 Sep;
167(1):260-274.e22.
PMID: 27641504
The inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured in pre-clinical models. We have created a large collection of breast cancer patient-derived tumor xenografts (PDTXs), in...
16.
Baird R, Banks I, Cameron D, Chester J, Earl H, Flannagan M, et al.
Ecancermedicalscience
. 2016 Feb;
10:608.
PMID: 26913066
The Association of Cancer Physicians in the United Kingdom has developed a strategy to improve outcomes for cancer patients and identified the goals and commitments of the Association and its...
17.
Sarker D, Ang J, Baird R, Kristeleit R, Shah K, Moreno V, et al.
Clin Cancer Res
. 2014 Nov;
21(1):77-86.
PMID: 25370471
Purpose: This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of pictilisib (GDC-0941), an oral, potent, and selective inhibitor...
18.
Yap T, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, et al.
Clin Cancer Res
. 2014 Sep;
20(22):5672-85.
PMID: 25239610
Purpose: Multiple cancers harbor genetic aberrations that impact AKT signaling. MK-2206 is a potent pan-AKT inhibitor with a maximum tolerated dose (MTD) previously established at 60 mg on alternate days...
19.
Venugopal B, Baird R, Kristeleit R, Plummer R, Cowan R, Stewart A, et al.
Clin Cancer Res
. 2013 Jun;
19(15):4262-72.
PMID: 23741066
Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic profile of quisinostat, a novel hydroxamate, pan-histone deacetylase inhibitor (HDACi). Experimental Design: In this first-in-human phase...
20.
He B, Baird R, Butera R, Datta A, George S, Hecht B, et al.
IEEE Trans Biomed Eng
. 2013 Feb;
60(3):589-98.
PMID: 23380847
This paper summarizes the discussions held during the First IEEE Life Sciences Grand Challenges Conference, held on October 4-5, 2012, at the National Academy of Sciences, Washington, DC, and the...